CTIS2023-505959-45-00招募中1 期
The effect of oral Semaglutide on bone turnover in patients with T2D: a randomized placebo-controlled clinical trial (SOBER II)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Type 2 diabetes and glycosylated haemoglobin (HbA1C) of 48-91 mmol/mol (6.5-10.5%) and, T-score <-1 in hip or lower back, assessed by DXA scan and / or, Low-energy fracture within the last 3 years
排除标准
- •T-score <-2.5 in hip or lower back, assessed by DXA scan, although these individuals may be included if they are not candidates for conventional osteoporosis therapy, e.g., due to allergies and renal impairment, or if they prefer to participate in the trial., Antiresorptive or bone anabolic drugs for the last 12 months, Use of anabolic steroids in the previous year, Use of GLP-1Ras within 90 days, Stable therapy with DPP4 inhibitors (unless the patient is willing to discontinue the treatment), History of pancreatitis, Allergy or hypersensitivity to the active substance or to any of the ingredients, Inability to give informed consent, Previous bariatric surgery, BMI <20 kg/m2 or BMI>37 kg/m2, Type 1 diabetes mellitus, Severe NPDR (non-proliferative diabetic retinopathy) or PDR (proliferative diabetic retinopathy) assessed within the last year. If a recent assessment is unavailable, a new retinal photo test will be performed., Congestive heart failure (NYHA Class IV), Primary hyperparathyroidism, Vitamin D deficiency (<25 nM) (re-test after substitution acceptable), Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe renal impairment (eGFR <30) or liver dysfunction (baseline phosphatase higher than twice upper limit (105 U/L)), rheumatism, celiac disease, hypogonadism, severe COPD, hypopituitarism, Cushing's disease, Clinically significant concomitant diseases or disorders (e.g., cancer) or clinically significant abnormal values in laboratory screening tests, including increased Choriogonadotropin (hCG) in women., History of gastrointestinal surgery (except uncomplicated surgical procedures such as hernia surgery and appendectomy)
研究者
相似试验
进行中（未招募）
2 期
The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical TrialOsteopeniaType 2 DiabetesNCT06050577Odense University Hospital64
进行中（未招募）
1 期
Does an approved treatment for type 2 diabetes decrease the risk of fractures in patients with type 2 diabetes?Type 2 diabetes mellitusMedDRA version: 19.0Level: LLTClassification code 10029505Term: Non-insulin-dependent diabetes mellitusSystem Organ Class: 100000004861EUCTR2015-001284-40-DKAarhus University Hospital60
Unknown
1 期
The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone FractureOsteopeniaNCT04702516Morten Frost64
已完成
不适用
The therapeutic effect of oral Semaglutide in older patients with type 2 diabetes mellitusJPRN-UMIN000048782Hokkaido University Graduate School30
招募中
4 期
Study for the efficacy and safety of oral semaglutide in subjects with type 2 diabetesType 2 diabetesJPRN-UMIN000050583Hokkaido University Hospital500